Acute lymphoblastic leukaemia: NCI risk group plus Toronto CNS-based stage.
The ALL — NCI/Rome Risk & Toronto Stage is a oncology scoring tool used in paediatric practice. Acute lymphoblastic leukaemia: NCI risk group plus Toronto CNS-based stage. It scores 3 criteria and interprets the total across 4 bands, so the number always arrives with the severity it implies rather than on its own. In PediAid each criterion is shown as a labelled option with the weight it carries, so the total can be checked rather than taken on trust.
3. They are Age at diagnosis; Presenting white cell count; CNS status (Toronto stage).
The total is interpreted as: any score - Standard risk · Stage I: nCI standard risk (age 1-9.99 y AND WBC <50 000) with no CNS disease - Toronto Stage I. Best prognosis; standard-intensity therapy; 1 risk point or more - Standard risk · CNS involvement: nCI standard risk but with CNS blasts - Toronto Stage II. Intensified CNS-directed therapy required; 2 risk points or more - High risk: nCI high risk (age <1 or ≥10 years, or WBC ≥50 000). Augmented therapy; check cytogenetics and MRD response; 3 risk points or more - High risk · CNS involvement: nCI high risk with CNS disease - Toronto Stage II. Most intensive therapy including CNS-directed treatment; MRD-guided escalation.
No. It is a structured way to record and communicate severity. A clinician concerned about a child should act on that concern regardless of the total.
Toronto Tier-1 stage for ALL: Stage I = no CNS disease (CNS1/CNS2); Stage II = CNS disease (CNS3).
Yes. Score definitions are bundled with the PediAid app, so the score computes without a connection.